Milestone Achieved: Metabolism and Target Organ Damage Publishes Over 100 Articles

We are proud to announce that Metabolism and Target Organ Damage（M&TOD）has published over 100 high-quality academic articles since its launch in September 2021. This achievement highlights the journal’s unwavering dedication to advancing research and sharing knowledge in the field of metabolic and therapeutic diseases.

Since its inception, M&TOD has focused on promoting groundbreaking research and fostering academic exchange in areas such as obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiometabolic disorders. Each published article showcases the hard work of researchers, the diligence of peer reviewers, and the continued support of our editorial team and readers worldwide.

Key Accomplishments:

• Growing International Recognition: Indexed by ESCI and Scopus, M&TOD is expected to receive its first Impact Factor (IF) by June 2025, with all articles indexed in the Web of Science Core Collection.
• Increasing Academic Impact: Many published articles have been widely cited by outstanding scholars, significantly advancing research in the field.

As we celebrate this achievement, we remain committed to publishing impactful research and providing a global platform for scientists. M&TOD will continue to emphasize quality, innovation, and accessibility, driving progress in the diagnosis, treatment, and prevention of metabolic diseases.

We extend heartfelt thanks to our Editor-in-Chief Prof. Amedeo Lonardo, for his invaluable contributions, support, and guidance, which have been instrumental in achieving this milestone. We also express our gratitude to every author, reviewer, and Editorial Board member for their essential roles. Together, we look forward to achieving even greater success in the future.

Editor: Alani Luo
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Metabolism and Target Organ Damage